PCA3 and neoplasm: Circulating tumour cells (CTCs) have been used as blood-based predictor of distant PCa metastasis [21]; and urinary expression of prostate cancer antigen 3 (PCA3), sarcosine and TMPRSS2:ERG fusion are also emerging markers of PCa risk stratification [19, 21].